Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3 -ITD+ AML Patients (pts)

Blood (2023) 142 (Supplement 1): 832.

https://doi.org/10.1182/blood-2023-186785

Published: 2023

Journal Articles

Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax

Muharrem Muftuoglu, Musa Yilmaz, Mahesh Basyal, Li Li, Takahiko Seki, Arnaud Lesegretain, Naval Daver, Michael Andreeff

Blood (2022) 140 (Supplement 1): 2273–2274.

https://doi.org/10.1182/blood-2022-171124

Published: 2022

Journal Articles

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Blood (2022) 140 (Supplement 1): 546–548.

https://doi.org/10.1182/blood-2022-162739

Published: 2022

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3 -Internal Tandem Duplication: Results from the Quantum-First Trial

Blood (2022) 140 (Supplement 1): 2130–2132.

https://doi.org/10.1182/blood-2022-169011

Published: 2022

Journal Articles

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Yuki Nishida, Jo Ishizawa, Edward Ayoub, Tallie Patsilevas, Lauren Ostermann, Rafael Heinz Montoya, Muharrem Muftuoglu, Vivian Ruvolo, Po Yee Mak, Wenjing Tao, Bing Z Carter, Kensuke Kojima, Naval Daver, Arnaud Lesegretain, Takahiko Seki, Sharon Shacham, Marina Konopleva, Michael Andreeff

Blood (2021) 138 (Supplement 1): 505.

https://doi.org/10.1182/blood-2021-149260

Published: 2021

Journal Articles

Single-Cell Proteomics Identifies Leukemia Landscape Associated with Clinical Outcomes in R/R AML Treated with MDM2i (Milademetan) and FLT3i (Quizartinib): Putative Role of CD68 and Diversity Index

Muharrem Muftuoglu, Li Li, Mahesh Basyal, Shaoheng Liang, Carissa J. Ball, Ken Chen, Prasanna Kumar, Arnaud Lesegretain, Naval Daver, Michael Andreeff

Blood (2021) 138 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2021-154376

Published: 2021

Journal Articles

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Yuki Nishida, MDPhD, Jo Ishizawa, MDPhD, Edward Ayoub, PhD MS, BSc, Rafael Heinz Montoya, BS, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Naval Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140768

Published: 2020

Journal Articles

FLT3 inhibitors added to induction therapy induce deeper remissions

Mark Levis, Wenge Shi, Ken Chang, Christian Laing, Reinhold Pollner, Christopher Gocke, Emily Adams, Flora Berisha, Jelveh Lameh, Arnaud Lesegretain

Blood (2020) 135 (1): 75–78.

https://doi.org/10.1182/blood.2019002180

Published: 2020

Includes: Supplemental data

Journal Articles

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Rafael Heinz Montoya, Naval G. Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2556.

https://doi.org/10.1182/blood-2019-126950

Published: 2019

Journal Articles

Characterization of Response and Transfusion Independence in Patients with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial

Mark J. Levis, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Arnaud Lesegretain, Jeanne Mendell, PhD MPH, Derek E. Mires, PharmD, Yufen Zhang, PhD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2599.

https://doi.org/10.1182/blood-2019-124491

Published: 2019

Journal Articles

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Siddhartha Ganguly, MD, Jorge E. Cortes, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Meena Arunachalam, PharmD, Guy Gammon, MBBS, MRCP, Arnaud Lesegretain, Derek E. Mires, PharmD, Ruth Namuyinga, MD MPH, Yufen Zhang, PhD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 736.

https://doi.org/10.1182/blood-2019-124504

Published: 2019

Journal Articles

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 737.

https://doi.org/10.1182/blood-2019-121880

Published: 2019

NARROW

Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3 -Internal Tandem Duplication: Results from the Quantum-First Trial

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Single-Cell Proteomics Identifies Leukemia Landscape Associated with Clinical Outcomes in R/R AML Treated with MDM2i (Milademetan) and FLT3i (Quizartinib): Putative Role of CD68 and Diversity Index

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

FLT3 inhibitors added to induction therapy induce deeper remissions

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

Characterization of Response and Transfusion Independence in Patients with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only